English | Français
English | Français
iC BIOSOLUTIONS is a pioneering biotech company dedicated to transforming the treatment of degenerative inflammation. Leveraging cutting-edge acellular regenerative technology, we develop advanced biologics that target the root causes of inflammatory and degenerative diseases.
Our lead product candidate focuses on equine arthritis, with plans to expand across species and into broader inflammatory conditions.
We introduce a new therapeutic class: a secretome-based acellular therapy for degenerative inflammatory diseases.
By removing inherent challenges of live-cell administration, secretome therapy offers a safer, more consistent, and more scalable alternative while maintaining robust regenerative and anti-inflammatory properties.
Validated through rigorous in vitro and ex vivo assays, it shows excellent tolerability and efficacy for clinical translation.
Stimulates cellular vitality
Restores function in damaged tissues, counteracts inflammation, and combats cellular senescence.
Highly tolerable
Minimal immunogenicity, no live cell implants, and reduced risk of adverse responses.
Clinically ready
Comprehensive data package supporting advancement into pivotal trials.
At iC BIOSOLUTIONS, our approach relies on differentiated stem cell banks derived from induced Pluripotent Stem Cells (iPS). These banks are produced under strict quality-controlled conditions to ensure reliability, consistency, and scalability for advanced biologic development.
Standardized
An unlimited, standardized source that eliminates reliance on human or animal tissues, enabling large-scale production.
Safe
A process guaranteeing consistent, reproducible and contaminant-free quality over time.
Our journey begins with equine osteoarthritis, an area of high unmet need and strong translational relevance.
Beyond osteoarthritis, our lead product candidate ICB001 targets core inflammatory and regenerative pathways shared across tissues and species, opening the door to future applications in a wide range of chronic degenerative and inflammatory diseases.
Horses
Our lead product candidate ICB001 focus on equine arthritis, with clinical validation underway.
Pets and humans
Future expansion to companion animals and, in the long term, human indications to address broader unmet needs.